Movement Alert｜10x Genomics, Inc. Intraday Rise 6.46% in Regular Trading, Raised Full-Year Revenue Outlook Keeps Earnings Debate Active

Market Focus11-11 22:49

On November 11, 10x Genomics, Inc. rose 6.46% in Regular Trading, trading near $65.92 per share, with turnover of $11.56 million.

The move followed continued market trading around the company’s better-than-expected quarterly results and raised full-year revenue guidance, even as post-earnings valuation debate has persisted.

In its latest quarterly report, 10x Genomics, Inc. posted a loss of $0.15 per share, better than market expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million exceeded consensus near $148 million. The company also lifted full-year revenue guidance to $625 million to $635 million, above the roughly $620.8 million market expectation. At the same time, some firms cut target prices after the report, indicating that stronger operating trends and valuation caution are still pulling sentiment in opposite directions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment